Does the media refer more to HRMY or CRNX?

In the previous week, Harmony Biosciences had 4 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for Harmony Biosciences and 1 mentions for Crinetics Pharmaceuticals. Harmony Biosciences' average media sentiment score of 1.00 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor HRMY or BLTE?

In the previous week, Harmony Biosciences and Harmony Biosciences both had 5 articles in the media. Harmony Biosciences' average media sentiment score of 1.00 beat Belite Bio's score of 0.20 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, LNTH or HRMY?

Lantheus has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.23 $233.56M $4.14 24.14 Harmony Biosciences $868.45M 2.66 $158.69M $3.08 12.87

Does the media refer more to LNTH or HRMY?

In the previous week, Lantheus had 4 more articles in the media than Harmony Biosciences. MarketBeat recorded 9 mentions for Lantheus and 5 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.00 beat Lantheus' score of 0.24 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harmony Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HRMY or AMRX?

In the previous week, Harmony Biosciences had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 5 mentions for Harmony Biosciences and 2 mentions for Amneal Pharmaceuticals. Harmony Biosciences' average media sentiment score of 1.00 beat Amneal Pharmaceuticals' score of 0.51 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, LQDA or HRMY?

Harmony Biosciences has higher revenue and earnings than Liquidia. Harmony Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 16.19 -$68.92M $1.37 20.91 Harmony Biosciences $868.45M 2.66 $158.69M $3.08 12.87

Does the media prefer LQDA or HRMY?

In the previous week, Liquidia had 33 more articles in the media than Harmony Biosciences. MarketBeat recorded 38 mentions for Liquidia and 5 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.00 beat Liquidia's score of 0.20 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 7 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral Harmony Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Harmony Biosciences (HRMY) Competitors

$39.64 +0.07 (+0.18%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$39.60 -0.04 (-0.10%)

As of 10/2/2026 07:30 PM Eastern

Compare

HRMY vs. CRNX, BLTE, LNTH, AMRX, and LQDA

Should you buy Harmony Biosciences stock or one of its competitors? Harmony Biosciences's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Belite Bio (BLTE), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), and Liquidia (LQDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Harmony Biosciences compare to Crinetics Pharmaceuticals?

Harmony Biosciences (NASDAQ:HRMY) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

In the previous week, Harmony Biosciences had 4 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for Harmony Biosciences and 1 mentions for Crinetics Pharmaceuticals. Harmony Biosciences' average media sentiment score of 1.00 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Harmony Biosciences has a net margin of 18.88% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Harmony Biosciences' return on equity of 20.06% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Harmony Biosciences has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market.

Harmony Biosciences currently has a consensus target price of $47.44, indicating a potential upside of 19.69%. Crinetics Pharmaceuticals has a consensus target price of $83.44, indicating a potential downside of 1.77%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Harmony Biosciences is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Harmony Biosciences has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.66	$158.69M	$3.08	12.87
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

Summary

Harmony Biosciences beats Crinetics Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

How does Harmony Biosciences compare to Belite Bio?

Harmony Biosciences (NASDAQ:HRMY) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Harmony Biosciences and Harmony Biosciences both had 5 articles in the media. Harmony Biosciences' average media sentiment score of 1.00 beat Belite Bio's score of 0.20 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Harmony Biosciences has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.66	$158.69M	$3.08	12.87
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Harmony Biosciences has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market.

Harmony Biosciences has a net margin of 18.88% compared to Belite Bio's net margin of 0.00%. Harmony Biosciences' return on equity of 20.06% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
Belite Bio	N/A	-11.84%	-11.62%

Harmony Biosciences presently has a consensus price target of $47.44, indicating a potential upside of 19.69%. Belite Bio has a consensus price target of $218.73, indicating a potential upside of 37.08%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts clearly believe Belite Bio is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Harmony Biosciences beats Belite Bio on 10 of the 14 factors compared between the two stocks.

How does Harmony Biosciences compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Harmony Biosciences has a net margin of 18.88% compared to Lantheus' net margin of 17.69%. Lantheus' return on equity of 28.10% beat Harmony Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Harmony Biosciences	18.88%	20.06%	14.15%

Lantheus has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.14
Harmony Biosciences	$868.45M	2.66	$158.69M	$3.08	12.87

Lantheus has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

Lantheus currently has a consensus target price of $108.11, suggesting a potential upside of 8.15%. Harmony Biosciences has a consensus target price of $47.44, suggesting a potential upside of 19.69%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Harmony Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

In the previous week, Lantheus had 4 more articles in the media than Harmony Biosciences. MarketBeat recorded 9 mentions for Lantheus and 5 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.00 beat Lantheus' score of 0.24 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harmony Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Harmony Biosciences on 9 of the 16 factors compared between the two stocks.

How does Harmony Biosciences compare to Amneal Pharmaceuticals?

Harmony Biosciences (NASDAQ:HRMY) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Harmony Biosciences has a net margin of 18.88% compared to Amneal Pharmaceuticals' net margin of 5.05%. Harmony Biosciences' return on equity of 20.06% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Harmony Biosciences presently has a consensus price target of $47.44, indicating a potential upside of 19.69%. Amneal Pharmaceuticals has a consensus price target of $21.00, indicating a potential upside of 3.45%. Given Harmony Biosciences' higher probable upside, research analysts clearly believe Harmony Biosciences is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Harmony Biosciences has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Harmony Biosciences has higher earnings, but lower revenue than Amneal Pharmaceuticals. Harmony Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.66	$158.69M	$3.08	12.87
Amneal Pharmaceuticals	$3.02B	2.15	$72.06M	$0.49	41.43

In the previous week, Harmony Biosciences had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 5 mentions for Harmony Biosciences and 2 mentions for Amneal Pharmaceuticals. Harmony Biosciences' average media sentiment score of 1.00 beat Amneal Pharmaceuticals' score of 0.51 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Harmony Biosciences beats Amneal Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Harmony Biosciences compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Harmony Biosciences has higher revenue and earnings than Liquidia. Harmony Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	16.19	-$68.92M	$1.37	20.91
Harmony Biosciences	$868.45M	2.66	$158.69M	$3.08	12.87

In the previous week, Liquidia had 33 more articles in the media than Harmony Biosciences. MarketBeat recorded 38 mentions for Liquidia and 5 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.00 beat Liquidia's score of 0.20 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	7 Very Positive mention(s)	8 Positive mention(s)	12 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral
Harmony Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

Liquidia presently has a consensus target price of $83.69, suggesting a potential upside of 192.22%. Harmony Biosciences has a consensus target price of $47.44, suggesting a potential upside of 19.69%. Given Liquidia's higher possible upside, equities analysts plainly believe Liquidia is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Liquidia has a net margin of 30.74% compared to Harmony Biosciences' net margin of 18.88%. Liquidia's return on equity of 149.65% beat Harmony Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Harmony Biosciences	18.88%	20.06%	14.15%

Summary

Liquidia beats Harmony Biosciences on 9 of the 17 factors compared between the two stocks.

Get Harmony Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRMY vs. The Competition

Export

Metric	Harmony Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.31B	$12.27B	$7.15B	$13.28B
Dividend Yield	N/A	2.65%	2.54%	17.33%
P/E Ratio	12.87	802.26	275.67	26.04
Price / Sales	2.66	940.01	656.66	111.00
Price / Cash	12.47	86.66	78.87	52.62
Price / Book	2.62	10.52	10.93	6.31
Net Income	$158.69M	$2.86B	$3.51B	$362.16M
7 Day Performance	-3.93%	-1.58%	-2.00%	-1.66%
1 Month Performance	-6.18%	-5.55%	-6.19%	-4.68%
1 Year Performance	45.31%	-2.19%	8.03%	1.57%

Harmony Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRMY Harmony Biosciences	4.818 of 5 stars	$39.64 +0.2%	$47.44 +19.7%	+45.3%	$2.31B	$868.45M	12.87	293	News Coverage Analyst Forecast
CRNX Crinetics Pharmaceuticals	0.8362 of 5 stars	$84.95 flat	$83.44 -1.8%	N/A	$9.01B	$7.70M	N/A	210
BLTE Belite Bio	3.324 of 5 stars	$165.93 -0.8%	$218.73 +31.8%	+111.1%	$6.74B	N/A	N/A	41
LNTH Lantheus	3.2301 of 5 stars	$99.74 flat	$108.11 +8.4%	+85.7%	$6.51B	$1.54B	24.09	1,193
AMRX Amneal Pharmaceuticals	3.1316 of 5 stars	$20.50 +3.7%	$21.00 +2.4%	+95.4%	$6.31B	$3.02B	41.84	8,500	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRMY) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harmony Biosciences (HRMY) Competitors

HRMY vs. CRNX, BLTE, LNTH, AMRX, and LQDA

How does Harmony Biosciences compare to Crinetics Pharmaceuticals?

Summary

How does Harmony Biosciences compare to Belite Bio?

Summary

How does Harmony Biosciences compare to Lantheus?

Summary

How does Harmony Biosciences compare to Amneal Pharmaceuticals?

Summary

How does Harmony Biosciences compare to Liquidia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY vs. The Competition

Harmony Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harmony Biosciences (HRMY) Competitors

HRMY vs. CRNX, BLTE, LNTH, AMRX, and LQDA

How does Harmony Biosciences compare to Crinetics Pharmaceuticals?

Does the media refer more to HRMY or CRNX?

Is HRMY or CRNX more profitable?

Which has more volatility & risk, HRMY or CRNX?

Do analysts recommend HRMY or CRNX?

Do institutionals and insiders believe in HRMY or CRNX?

Which has higher earnings & valuation, HRMY or CRNX?

Summary

How does Harmony Biosciences compare to Belite Bio?

Does the media favor HRMY or BLTE?

Which has preferable valuation and earnings, HRMY or BLTE?

Which has more risk & volatility, HRMY or BLTE?

Is HRMY or BLTE more profitable?

Do analysts rate HRMY or BLTE?

Do insiders and institutionals believe in HRMY or BLTE?

Summary

How does Harmony Biosciences compare to Lantheus?

Do insiders & institutionals have more ownership in LNTH or HRMY?

Is LNTH or HRMY more profitable?

Which has better earnings and valuation, LNTH or HRMY?

Which has more volatility and risk, LNTH or HRMY?

Do analysts recommend LNTH or HRMY?

Does the media refer more to LNTH or HRMY?

Summary

How does Harmony Biosciences compare to Amneal Pharmaceuticals?

Do institutionals and insiders believe in HRMY or AMRX?

Is HRMY or AMRX more profitable?

Do analysts rate HRMY or AMRX?

Which has more volatility and risk, HRMY or AMRX?

Which has better valuation & earnings, HRMY or AMRX?

Does the media refer more to HRMY or AMRX?

Summary

How does Harmony Biosciences compare to Liquidia?

Which has preferable valuation & earnings, LQDA or HRMY?

Does the media prefer LQDA or HRMY?

Which has more risk and volatility, LQDA or HRMY?

Do analysts prefer LQDA or HRMY?

Do institutionals & insiders have more ownership in LQDA or HRMY?

Is LQDA or HRMY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY vs. The Competition

Harmony Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools